Alendronate Increases Bone Density in Osteoporotic Women
Author Information
Author(s): Qin Ling, Choy Wingyee, Au Szeki, Fan Musei, Leung Pingchung
Primary Institution: The Chinese University of Hong Kong
Hypothesis
Does 12-month Alendronate treatment improve bone mineral density in postmenopausal women with established osteoporosis?
Conclusion
12 months of Alendronate treatment effectively increased bone mineral density in both axial and appendicular skeletons of postmenopausal women with established osteoporosis.
Supporting Evidence
- Alendronate treatment increased BMD by 5.1% at the spine and 2.5% at the hip after 12 months.
- The placebo group showed no significant change in BMD.
- Bone turnover markers decreased significantly in the Alendronate group.
Takeaway
This study shows that taking Alendronate for a year helps make bones stronger in older women who have weak bones.
Methodology
118 postmenopausal women aged 50 to 75 were treated with Alendronate or placebo for 12 months, measuring bone mineral density at various sites.
Potential Biases
Potential bias in participant selection and dropout rates.
Limitations
The study duration was only 12 months, which may not capture long-term effects.
Participant Demographics
Postmenopausal Chinese women aged 50 to 75 with low-energy fractures.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website